In Vitro-In Vivo Correlation Strategy Applied to an Immediate-Release Solid Oral Dosage Form with a Biopharmaceutical Classification System IV Compound Case Study

被引:13
作者
Bredael, Gerard M. [1 ]
Bowers, Niya [2 ]
Boulineau, Fabien [3 ]
Hahn, David [3 ]
机构
[1] Merck, Preformulat, Pharmaceut Sci & Clin Supply, Summit, NJ 07901 USA
[2] Merck, ADC API & PAT, Analyt Chem Dev & Supply, Rahway, NJ USA
[3] Merck, Analyt Sci, Pharmaceut Sci & Clin Supply, Summit, NJ USA
关键词
dissolution; in vitro; in vivo correlations (IVIVC); in vitro models; oral drug delivery; mathematical models; FORMULATION; IVIVC; LEVEL;
D O I
10.1002/jps.24036
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The ability to predict in vivo response of an oral dosage form based on an in vitro technique has been a sought after goal of the pharmaceutical scientist. Dissolution testing that demonstrates discrimination to various critical formulations or process attributes provides a sensitive quality check that may be representative or may be overpredictive of potential in vivo changes. Dissolution methodology with an established in vitro-in vivo relationship or correlation may provide the desired in vivo predictability. To establish this in vitro-in vivo link, a clinical study must be performed. In this article, recommendations are given in the selection of batches for the clinical study followed by potential outcome scenarios. The investigation of a Level C in vitro-in vivo correlation (IVIVC), which is the most common correlation for immediate-release oral dosage forms, is presented. Lastly, an IVIVC case study involving a biopharmaceutical classification system class IV compound is presented encompassing this strategy and techniques. (c) 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:2125-2130, 2014
引用
收藏
页码:2125 / 2130
页数:6
相关论文
共 15 条
[1]  
[Anonymous], 1997, GUID IND DISS TEST I
[2]  
Brown CynthiaK., 2004, Pharmaceutical Technology, P56, DOI [10.14227/DT110204P28, DOI 10.14227/DT110204P28]
[3]   Development strategies for IVIVC in an industrial environment [J].
Cook, Jack A. .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2012, 33 (07) :349-353
[4]  
FDA, 1997, EXT REL OR DOS FORMS
[5]  
Hawley M, 2013, AM PHARM REV, V16, P32
[6]   Analysis of level A in vitro-in vivo correlations for an extended-release formulation with limited bioavailability [J].
Kakhi, Maziar ;
Marroum, Patrick ;
Chittenden, Jason .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2013, 34 (05) :262-277
[7]   Level A in vitro-in vivo correlation (IVIVC) model with Bayesian approach to formulation series [J].
Kortejarvi, H. ;
Malkki, J. ;
Marvola, M. ;
Urtti, A. ;
Yliperttula, M. ;
Pajunen, P. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (07) :1595-1605
[8]   IV-IVC considerations in the development of immediate-release oral dosage form [J].
Li, SF ;
He, HD ;
Parthiban, LJ ;
Yin, HQ ;
Serajuddin, ATM .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (07) :1396-1417
[9]   Regulatory status on the role of in vitro dissolution testing in quality control and biopharmaceutics in Europe [J].
Limberg, Jobst ;
Potthast, Henrike .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2013, 34 (05) :247-253
[10]   Influence of Drug Property and Product Design on In Vitro-In Vivo Correlation of Complex Modified-Release Dosage Forms [J].
Qiu, Yihong ;
Li, Xia ;
Duan, John Z. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 103 (02) :507-516